TABLE 1.
Parameter | TAF | TDF |
---|---|---|
No. of patients phenotyped (% of patients sequenced) | 18 (19) | 7 (15) |
Virologic breakthrough without nonadherence | 13 | 7 |
Conserved site changes | 5 | 0 |
Mean EC50 fold change from baseline | 1.03 | 0.94 |
Range of fold change from baseline | 0.39–1.51 | 0.63–1.69 |